Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia.

Wayne Fenton was a major driving force behind the establishment of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) and Treatment Units for Research on Neurocognition and Schizophrenia (TURNS) project mechanisms. These projects were designed to facilitate the development of new drugs for the treatment of cognitive impairments in people with schizophrenia. The MATRICS project identified 3 drug mechanisms of particular interest: cholinergic, dopaminergic, and glutamatergic. The TURNS project is designed to select potential cognitive-enhancing agents and evaluate their potential efficacy in the context of proof of concept or clinical efficacy trials. This article reviews the rationale for these 3 approaches and provides an update on the development of therapeutic agents, which act through one of these 3 mechanisms.

[1]  Michael F. Green,et al.  A Placebo-Controlled Add-On Trial of the Ampakine, CX516, for Cognitive Deficits in Schizophrenia , 2008, Neuropsychopharmacology.

[2]  D. Javitt,et al.  The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. , 2007, The American journal of psychiatry.

[3]  R. Mailman,et al.  A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia , 2007, Schizophrenia Research.

[4]  T. Nabeshima,et al.  The Allosteric Potentiation of Nicotinic Acetylcholine Receptors by Galantamine Ameliorates the Cognitive Dysfunction in Beta Amyloid25–35 I.c.v.-Injected Mice: Involvement of Dopaminergic Systems , 2007, Neuropsychopharmacology.

[5]  Michael F. Green,et al.  Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. , 2007, Archives of general psychiatry.

[6]  Young Hoon Kim,et al.  A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia , 2007, International clinical psychopharmacology.

[7]  H. Lublin,et al.  Effects of Donepezil Adjunctive Treatment to Ziprasidone on Cognitive Deficits in Schizophrenia: A Double-blind, Placebo-Controlled Study , 2007, Clinical neuropharmacology.

[8]  Brandon J. Margolis,et al.  Design, synthesis, structure-activity relationship, and in vivo activity of azabicyclic aryl amides as alpha7 nicotinic acetylcholine receptor agonists. , 2006, Bioorganic & medicinal chemistry.

[9]  S. Gauthier,et al.  Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy. , 2006, Journal of psychiatry & neuroscience : JPN.

[10]  T. George,et al.  A preliminary study of the effects of cigarette smoking on prepulse inhibition in schizophrenia: Involvement of nicotinic receptor mechanisms , 2006, Schizophrenia Research.

[11]  Keith A. Young,et al.  Galantamine Improves Cognition in Schizophrenic Patients Stabilized on Risperidone , 2006, Biological Psychiatry.

[12]  Yue-Cune Chang,et al.  Glycine Transporter I Inhibitor, N-methylglycine (Sarcosine), Added to Clozapine for the Treatment of Schizophrenia , 2006, Biological Psychiatry.

[13]  T. Sharma,et al.  Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: A randomized, placebo-controlled, double-blind investigation , 2006, Schizophrenia Research.

[14]  Robert Freedman,et al.  Proof-of-Concept Trial of an α7 Nicotinic Agonist in Schizophrenia , 2006 .

[15]  Robert C. Smith,et al.  Effects of Nicotine Nasal Spray on Cognitive Function in Schizophrenia , 2006, Neuropsychopharmacology.

[16]  Yue-Cune Chang,et al.  D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia , 2006, Biological Psychiatry.

[17]  P. Conn,et al.  Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors. , 2006, Current opinion in pharmacology.

[18]  R. Depoortère,et al.  Neurochemical, Electrophysiological and Pharmacological Profiles of the Selective Inhibitor of the Glycine Transporter-1 SSR504734, a Potential New Type of Antipsychotic , 2005, Neuropsychopharmacology.

[19]  Chih-Chiang Chiu,et al.  Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. , 2005, Archives of general psychiatry.

[20]  Xu-Feng Huang,et al.  Decreased density of muscarinic receptors in the superior temporal gyrusin schizophrenia , 2005, Journal of neuroscience research.

[21]  Herbert Y Meltzer,et al.  A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. , 2005, The international journal of neuropsychopharmacology.

[22]  Robert E Hampson,et al.  Facilitation of Task Performance and Removal of the Effects of Sleep Deprivation by an Ampakine (CX717) in Nonhuman Primates , 2005, PLoS biology.

[23]  D. Palumbo,et al.  Efficacy and Tolerability of Low-Dose Donepezil in Schizophrenia , 2005, Clinical neuropharmacology.

[24]  K. Hashimoto,et al.  Tropisetron improves deficits in auditory P50 suppression in schizophrenia , 2005, Schizophrenia Research.

[25]  Suchitra Krishnan-Sarin,et al.  Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. , 2005, Archives of general psychiatry.

[26]  D. Cyril D’Souza,et al.  Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects , 2005, Psychopharmacology.

[27]  D. Goff,et al.  A six-month, placebo-controlled trial of d-cycloserine co-administered with conventional antipsychotics in schizophrenia patients , 2005, Psychopharmacology.

[28]  D. Goff,et al.  Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial , 2005, Psychopharmacology.

[29]  Daniel C. Javitt,et al.  D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia , 2005, Biological Psychiatry.

[30]  D. Javitt,et al.  Inhibition of System A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action , 2005, Molecular Psychiatry.

[31]  Michael F. Green,et al.  Identification of separable cognitive factors in schizophrenia , 2004, Schizophrenia Research.

[32]  M. Kotler,et al.  Rivastigmine augmentation in the management of chronic schizophrenia with comorbid dementia: an open-label study investigating effects on cognition, behaviour and activities of daily living , 2004, International clinical psychopharmacology.

[33]  H. Meltzer,et al.  Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism , 2004, Brain Research.

[34]  Robert Freedman,et al.  Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. , 2004, The American journal of psychiatry.

[35]  Abraham Weizman,et al.  Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross‐over study , 2004, Human psychopharmacology.

[36]  R. Freedman,et al.  Effects of Nicotine on Cognitive Deficits in Schizophrenia , 2004, Neuropsychopharmacology.

[37]  R. Papke,et al.  The structural basis for GTS-21 selectivity between human and rat nicotinic alpha7 receptors. , 2004, Molecular pharmacology.

[38]  Aaron L Mishara,et al.  A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book , 2004, Biological Psychiatry.

[39]  P. Skudlarski,et al.  Nicotine effects on brain function and functional connectivity in schizophrenia , 2004, Biological Psychiatry.

[40]  M. Geyer,et al.  Measurement and treatment research to improve cognition in schizophrenia: neuropharmacological aspects , 2004, Psychopharmacology.

[41]  G. Thaker,et al.  Nicotine improves delayed recognition in schizophrenic patients , 2004, Psychopharmacology.

[42]  Nicholas Lange,et al.  Glycine transporter I inhibitor, N-Methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia , 2004, Biological Psychiatry.

[43]  P. Goldman-Rakic,et al.  Enhancement of Working Memory in Aged Monkeys by a Sensitizing Regimen of Dopamine D1 Receptor Stimulation , 2004, The Journal of Neuroscience.

[44]  Shan Xie,et al.  Reversal of Phencyclidine-Induced Dopaminergic Dysregulation by N-Methyl-D-Aspartate Receptor/Glycine-site Agonists , 2004, Neuropsychopharmacology.

[45]  D. Javitt,et al.  Comparative effects of glycine and d-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis , 2004, Schizophrenia Research.

[46]  G. Jaskiw,et al.  A meta-analysis of the response to chronic l-dopa in patients with schizophrenia: therapeutic and heuristic implications , 2004, Psychopharmacology.

[47]  A. Carlsson,et al.  Schizophrenia: from dopamine to glutamate and back. , 2004, Current medicinal chemistry.

[48]  D. Javitt,et al.  High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia , 2004, Biological Psychiatry.

[49]  G. Thaker,et al.  Effects of Nicotine on Leading Saccades during Smooth Pursuit Eye Movements in Smokers and Nonsmokers with Schizophrenia , 2003, Neuropsychopharmacology.

[50]  Edilio Borroni,et al.  Prepulse inhibition deficits of the startle reflex in neonatal ventral hippocampal–lesioned rats: reversal by glycine and a glycine transporter inhibitor , 2003, Biological Psychiatry.

[51]  Enzo Poggi,et al.  Effects of Rivastigmine on Cognitive Function and Quality of Life in Patients With Schizophrenia , 2003, Clinical neuropharmacology.

[52]  S. Wonnacott,et al.  The allosteric potentiation of nicotinic acetylcholine receptors by galantamine is transduced into cellular responses in neurons: Ca2+ signals and neurotransmitter release. , 2003, Molecular pharmacology.

[53]  P. Mallorga,et al.  The Glycine Transporter Type 1 Inhibitor N-[3-(4′-Fluorophenyl)-3-(4′-Phenylphenoxy)Propyl]Sarcosine Potentiates NMDA Receptor-Mediated Responses In Vivo and Produces an Antipsychotic Profile in Rodent Behavior , 2003, The Journal of Neuroscience.

[54]  Martin Radina,et al.  Galantamine Is an Allosterically Potentiating Ligand of Neuronal Nicotinic but Not of Muscarinic Acetylcholine Receptors , 2003, Journal of Pharmacology and Experimental Therapeutics.

[55]  É. Schmidt,et al.  The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study , 2003, Pharmacology Biochemistry and Behavior.

[56]  D. Barch,et al.  Working memory and prefrontal cortex dysfunction: specificity to schizophrenia compared with major depression , 2003, Biological Psychiatry.

[57]  Charles R. Yang,et al.  Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. , 2003, Journal of neurophysiology.

[58]  R. Freedman,et al.  Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism , 2003, Psychopharmacology.

[59]  Robert W. Buchanan,et al.  An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia , 2003, Schizophrenia Research.

[60]  S. Lal,et al.  Nicotine and Behavioral Markers of Risk for Schizophrenia: A Double-Blind, Placebo-Controlled, Cross-Over Study , 2002, Neuropsychopharmacology.

[61]  M. Egan,et al.  Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series , 2002, Schizophrenia Research.

[62]  Robert C. Smith,et al.  Effects of Cigarette Smoking and Nicotine Nasal Spray on Psychiatric Symptoms and Cognition In Schizophrenia , 2002, Neuropsychopharmacology.

[63]  R. Mailman,et al.  Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. , 2002, The Journal of pharmacology and experimental therapeutics.

[64]  R. Mailman,et al.  Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs. , 2002, The Journal of pharmacology and experimental therapeutics.

[65]  R. V. Van Heertum,et al.  Prefrontal Dopamine D1 Receptors and Working Memory in Schizophrenia , 2002, The Journal of Neuroscience.

[66]  Philip D. Harvey,et al.  A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia , 2002, Biological Psychiatry.

[67]  R. Vandenberg,et al.  N[3‐(4′‐fluorophenyl)‐3‐(4′‐phenylphenoxy)propyl]sarcosine (NFPS) is a selective persistent inhibitor of glycine transport , 2001, British journal of pharmacology.

[68]  V. Ognyanov,et al.  ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter. , 2001, Molecular pharmacology.

[69]  D. Javitt,et al.  Adjunctive high-dose glycine in the treatment of schizophrenia. , 2001, The international journal of neuropsychopharmacology.

[70]  Andrew C. Leon,et al.  A Placebo-Controlled Pilot Study of the Ampakine CX516 Added to Clozapine in Schizophrenia , 2001, Journal of clinical psychopharmacology.

[71]  G. Walker,et al.  Discovery and SAR of org 24598-a selective glycine uptake inhibitor. , 2001, Bioorganic & medicinal chemistry letters.

[72]  A. Brown,et al.  Pharmacological assessment of the role of the glycine transporter GlyT-1 in mediating high-affinity glycine uptake by rat cerebral cortex and cerebellum synaptosomes , 2001, Neuropharmacology.

[73]  B. Dean,et al.  Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. , 2001, The American journal of psychiatry.

[74]  D. Durstewitz,et al.  Bidirectional Dopamine Modulation of GABAergic Inhibition in Prefrontal Cortical Pyramidal Neurons , 2001, The Journal of Neuroscience.

[75]  J. Haxby,et al.  Cholinergic enhancement and increased selectivity of perceptual processing during working memory. , 2000, Science.

[76]  A. C. Collins,et al.  Abnormal Regulation of High Affinity Nicotinic Receptors in Subjects with Schizophrenia , 2000, Neuropsychopharmacology.

[77]  Jeremy M Crook,et al.  Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation , 2000, Biological Psychiatry.

[78]  A. Maelicke,et al.  Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. , 2000, European journal of pharmacology.

[79]  P. Goldman-Rakic,et al.  Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. , 2000, Science.

[80]  P. Goldman-Rakic,et al.  D1 receptors in prefrontal cells and circuits , 2000, Brain Research Reviews.

[81]  J. Gold,et al.  Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia I: sensitivity, reliability, and validity. , 1999, The American journal of psychiatry.

[82]  A. Sampson,et al.  Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. , 1999, The American journal of psychiatry.

[83]  J. McEvoy,et al.  Smoking and therapeutic response to clozapine in patients with schizophrenia , 1999, Biological Psychiatry.

[84]  K. Blennow,et al.  Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. , 1999, Neuroreport.

[85]  G. Rogers,et al.  Synergistic interactions between ampakines and antipsychotic drugs. , 1999, The Journal of pharmacology and experimental therapeutics.

[86]  A. Lajtha,et al.  Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors , 1999, Biological Psychiatry.

[87]  J. Coyle,et al.  Modulation of N-methyl-D-aspartate receptor function by glycine transport. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[88]  Nicholas Lange,et al.  D-serine added to antipsychotics for the treatment of schizophrenia , 1998, Biological Psychiatry.

[89]  P. Blanchet,et al.  Effects of the Full Dopamine Dl Receptor Agonist Dihydrexidine in Parkinson's Disease , 1998, Clinical neuropharmacology.

[90]  B. Moghaddam,et al.  Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. , 1998, Science.

[91]  T. Goldberg,et al.  Capacity limitations in short-term memory in schizophrenia: tests of competing hypotheses , 1998, Psychological Medicine.

[92]  G. Lynch,et al.  Facilitative Effects of the Ampakine CX516 on Short-Term Memory in Rats: Enhancement of Delayed-Nonmatch-to-Sample Performance , 1998, The Journal of Neuroscience.

[93]  R. Freedman,et al.  Selective α7-nicotinic agonists normalize inhibition of auditory response in DBA mice , 1998, Psychopharmacology.

[94]  D. Murphy,et al.  The Influence of Ondansetron and m-Chlorophenylpiperazine on Scopolamine-Induced Cognitive, Behavioral, and Physiological Responses in Young Healthy Controls , 1998, Biological Psychiatry.

[95]  A. Lajtha,et al.  Reversal of Phencyclidine-Induced Hyperactivity by Glycine and the Glycine Uptake Inhibitor Glycyldodecylamide , 1997, Neuropsychopharmacology.

[96]  Robert Freedman,et al.  Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers , 1997, Biological Psychiatry.

[97]  D. Weinberger,et al.  Dopamine, the prefrontal cortex and schizophrenia , 1997, Journal of psychopharmacology.

[98]  CR Yang,et al.  Dopamine D1 receptor actions in layers V-VI rat prefrontal cortex neurons in vitro: modulation of dendritic-somatic signal integration , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[99]  Michael F. Green,et al.  What are the functional consequences of neurocognitive deficits in schizophrenia? , 1996, The American journal of psychiatry.

[100]  D E Nichols,et al.  Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping. , 1996, Journal of medicinal chemistry.

[101]  S. Woods,et al.  Effects of clozapine on smoking in chronic schizophrenic outpatients. , 1995, The Journal of clinical psychiatry.

[102]  R. Freedman,et al.  Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia , 1995, Biological Psychiatry.

[103]  D. Mckenna,et al.  Human α 7 nicotinic acetylcholine receptor responses to novel ligands , 1995, Neuropharmacology.

[104]  Christer Halldin,et al.  Distribution of D1- and D2-Dopamine Receptors, and Dopamine and Its Metabolites in the Human Brain , 1994, Neuropsychopharmacology.

[105]  P. Goldman-Rakic,et al.  Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys , 1994, Psychopharmacology.

[106]  D. Javitt,et al.  Amelioration of negative symptoms in schizophrenia by glycine. , 1994, The American journal of psychiatry.

[107]  R. Mailman,et al.  Dopaminergic benzo[a]phenanthridines: resolution and pharmacological evaluation of the enantiomers of dihydrexidine, the full efficacy D1 dopamine receptor agonist. , 1994, Journal of medicinal chemistry.

[108]  W. Brewster,et al.  Dihydrexidine: a new potent peripheral dopamine D1 receptor agonist. , 1993, European journal of pharmacology.

[109]  R. Mailman,et al.  Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist. , 1992, The Journal of pharmacology and experimental therapeutics.

[110]  R. Mailman,et al.  Behavioral effects in the rat of dihydrexidine, a high-potency, full-efficacy D1 dopamine receptor agonist. , 1991, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[111]  K. Davis,et al.  Dopamine in schizophrenia: a review and reconceptualization. , 1991, The American journal of psychiatry.

[112]  D. Javitt,et al.  Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.

[113]  P. Goldman-Rakic,et al.  D1 dopamine receptors in prefrontal cortex: involvement in working memory , 1991, Science.

[114]  P. Goldman-Rakic,et al.  Autoradiographic comparison of D1-specific binding of [3H]SCH39166 and SCH23390 in the primate cerebral cortex , 1990, Brain Research.

[115]  R. Mailman,et al.  trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist. , 1990, Journal of Medicinal Chemistry.

[116]  G. Vauquelin,et al.  Evidence for a widespread dopaminergic innervation of the human cerebral neocortex , 1989, Neuroscience Letters.

[117]  R. Mailman,et al.  Dihydrexidine, a novel selective high potency full dopamine D-1 receptor agonist. , 1989, European journal of pharmacology.

[118]  P Riederer,et al.  Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. , 1987, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[119]  S S Stensaas,et al.  Autoradiographic Evidence of [3H]SCH 23390 Binding Site; in Human Prefrontal Cortex (Brodmann's Area 9) , 1987, Journal of neurochemistry.

[120]  D. Weinberger.  Implications of normal brain development for the pathogenesis of schizophrenia. , 1987, Archives of general psychiatry.

[121]  T. Crow.  Positive and Negative Schizophrenia Symptoms and the Role of Dopamine , 1981, British Journal of Psychiatry.

[122]  C. Carter,et al.  Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats , 1980, Nature.

[123]  A. Carlsson.  Does dopamine play a role in schizophrenia? , 1977, Psychological Medicine.

[124]  T. Svensson,et al.  Galantamine Enhances Dopaminergic Neurotransmission In Vivo Via Allosteric Potentiation of Nicotinic Acetylcholine Receptors , 2007, Neuropsychopharmacology.

[125]  K. Stephan,et al.  Nicotinic modulation of human auditory sensory memory: Evidence from mismatch negativity potentials. , 2006, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.

[126]  R. Papke,et al.  Hydroxy metabolites of the Alzheimer's drug candidate 3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (GTS-21): their molecular properties, interactions with brain nicotinic receptors, and brain penetration. , 2004, Molecular pharmacology.

[127]  J. Lieberman,et al.  Provocative tests with psychostimulant drugs in schizophrenia , 2004, Psychopharmacology.

[128]  Douglas W. Jones,et al.  In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. , 2003, The American journal of psychiatry.

[129]  B. Wexler,et al.  Effects of Smoking Abstinence on Visuospatial Working Memory Function in Schizophrenia , 2002, Neuropsychopharmacology.

[130]  D E Nichols,et al.  D1 dopamine receptors. , 2001, International review of neurobiology.

[131]  J. Cummings,et al.  Cholinesterase inhibitors: A new class of psychotropic compounds. , 2000, The American journal of psychiatry.

[132]  D. Javitt,et al.  Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. , 1999, Archives of general psychiatry.

[133]  R Freedman,et al.  Schizophrenia, sensory gating, and nicotinic receptors. , 1998, Schizophrenia bulletin.

[134]  S. R. Nash,et al.  Dopamine receptors: from structure to function. , 1998, Physiological reviews.

[135]  D. Murphy,et al.  Cognitive and Behavioral Effects of Cholinergic, Dopaminergic, and Serotonergic Blockade in Humans , 1997, Neuropsychopharmacology.

[136]  D. Mckenna,et al.  Human alpha 7 nicotinic acetylcholine receptor responses to novel ligands. , 1995, Neuropharmacology.

[137]  R. Papke,et al.  Characterization of a series of anabaseine-derived compounds reveals that the 3-(4)-dimethylaminocinnamylidine derivative is a selective agonist at neuronal nicotinic alpha 7/125I-alpha-bungarotoxin receptor subtypes. , 1995, Molecular pharmacology.

[138]  A Carlsson,et al.  Schizophrenia: a subcortical neurotransmitter imbalance syndrome? , 1990, Schizophrenia bulletin.

[139]  H. Meltzer,et al.  Psychopharmacology : the third generation of progress , 1987 .

[140]  H. Maeno,et al.  Dopamine Receptors , 2018 .

[141]  S. Stahl,et al.  The dopamine hypothesis of schizophrenia: a review. , 1976, Schizophrenia bulletin.